

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3600122

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ANN TAYLOR	09/25/2012
LLOYD B KLINKSTEIN	09/25/2012
RECEIVING PARTY DATA	
Name:	NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
Street Address:	220 MASSACHUSETTS AVENUE
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02139
PROPERTY NUMBERS Total: 3	
Property Type	Number
PCT Number:	US2012053844
Application Number:	61638588
Application Number:	61532459
CORRESPONDENCE DATA	
Fax Number:	(760)720-1330
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	760-720-1330
Email:	jessica@wolffip.com
Correspondent Name:	WOLFF IP, A PROF. CORP.
Address Line 1:	4510 PARK DRIVE
Address Line 4:	CARLSBAD, CALIFORNIA 92008
ATTORNEY DOCKET NUMBER:	PAT054764-US-PCT
NAME OF SUBMITTER:	JESSICA R. WOLFF
SIGNATURE:	/Jessica R. Wolff/
DATE SIGNED:	11/03/2015
Total Attachments: 5	
source=PAT054764 - Formal Documents - G DRIVE UPLOAD-266982#page4.tif	
source=PAT054764 - Formal Documents - G DRIVE UPLOAD-266982#page5.tif	
source=PAT054764 - Formal Documents - G DRIVE UPLOAD-266982#page6.tif	

source=PAT054764 - Formal Documents - G DRIVE UPLOAD-266982#page7.tif

source=PAT054764 - Formal Documents - G DRIVE UPLOAD-266982#page8.tif

ASSIGNMENT

This Assignment Agreement is entered into by and between

- | | | |
|------------------------|--------------------------|------------------------------------------------------------------------------------------------------------------------|
| 1. Ann TAYLOR | citizen of United States | Novartis Institutes for BioMedical Research, Inc.
220 Massachusetts Avenue
Cambridge, Massachusetts 02139
USA |
| 2. Lloyd B. KLINKSTEIN | citizen of United States | Novartis Institutes for BioMedical Research, Inc.
220 Massachusetts Avenue
Cambridge, Massachusetts 02139
USA |

(hereinafter "Inventor(s)"), and Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts, 02139, USA, a company organized under the laws of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, Novartis Institutes for BioMedical Research, Inc. is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to Novartis Institutes for BioMedical Research, Inc. and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

**USE OF AN AROMATASE INHIBITOR FOR THE
TREATMENT OF HYPOGONADISM AND RELATED DISEASES**

and filed in the European Office on _____ and accorded Application Number _____ and/or filed as a PCT International Application on September 6, 2012 and accorded International Patent Application Number PCT/US2012/053844 and/or filed in the

United States Patent and Trademark Office on September 8, 2011 and accorded Application Number 61/532,459 and on April 26, 2012 and accorded Application Number 61/638,588;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be

granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 25 day of Sept, 2012.

Ann Taylor L.S.
Ann TAYLOR

Carrie Mater
Witness
Print Name: Carrie Mater

D. LaFrance
Witness
Print Name: D. LaFrance

Executed this 25 day of SEPT, 2012.

Lloyd B. Klickstein L.S.
Lloyd B. KLICKSTEIN

D. LaFrance
Witness
Print Name: D. LaFrance

Carrie Mater
Witness
Print Name: Carrie Mater

Executed this 1st day of October, 2012.

Acceptance of Company

BY: Yelissa Ponzani L.S.
Novartis Institutes for BioMedical Research, Inc.

Patricia Hofstetter
Witness PATRICIA HOFSTETTER
Print Name: AUTHORIZED SIGNATORY

Marilyn Murphy
Witness
Print Name: Marilyn Murphy